Quantinuum plans to sell nearly 21.1 million shares at between $45 and $50 each in the IPO.

By Colin Kellaher Quantinuum unveiled terms of a planned initial public offering that could give the quantum-computing company majority-owned by Honeywell International an initial market capitalization approaching $13 billion. Quantinuum on Tuesday said it plans to sell nearly 21.1 million shares at between $45 and $50 each in the IPO. At the $47.50 midpoint of that range, the Broomfield, Colo., company said it expects net proceeds of about $941.7 million, or roughly $1.09 billion if the underwriters exercise an option to buy an additional 3.16 million shares. Quantinuum, which was formed in 2021 through the merger of Honeywell Quantum Solutions with U.K.-based start-up Cambridge Quantum Computing, said it would have about 257.1 million shares outstanding after the IPO, assuming an exercise of the overallotment option, for a market capitalization of nearly $12.9 billion at the $50-a-share pricing high end. Honeywell currently owns nearly 55% of Quantinuum, while entities affiliated with Cambridge Quantum own roughly 36%. Quantinuum last year announced a $600 million equity capital fundraise at a premoney valuation of $10 billion. The Commerce Department last week said the Trump administration is awarding $2 billion in grants to nine quantum-computing companies, including Quantinuum, in deals that include U.S. government receiving a minority, non-controlling equity stakes in the companies. Quantinuum will receive up to $100 million in funding, including an initial $56 million. Quantinuum said it will apply to list its shares on the Nasdaq Global Market under the symbol QNT. Write to Colin Kellaher at [email protected] (END) Dow Jones Newswires 05-26-26 0805ET

Physicists at the University of Oxford show they can assemble Schrödinger’s cat-like superpositions from far more exotic quantum ingredients.

Selection marks the next phase of construction on Micron’s New York project, expected to generate 50,000 jobs.

OneAdvanced has launched what it bills as the UK’s first private, sovereign healthcare large language model trained on NHS primary-care data.